Cargando…
Evidence‐based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease
Type 2 diabetes is the leading cause of chronic kidney disease (CKD). The prevalence of CKD is growing in parallel with the rising number of patients with type 2 diabetes globally. At present, the optimal approach to glycaemic control in patients with type 2 diabetes and advanced CKD (categories 4 a...
Autores principales: | Tuttle, Katherine R., McGill, Janet B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317405/ https://www.ncbi.nlm.nih.gov/pubmed/32009296 http://dx.doi.org/10.1111/dom.13986 |
Ejemplares similares
-
Mechanisms and clinical applications of incretin therapies for diabetes and chronic kidney disease
por: Alicic, Radica Z., et al.
Publicado: (2023) -
The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes
por: Triplitt, Curtis, et al.
Publicado: (2007) -
Incretins in the Therapy of Diabetic Kidney Disease
por: Przezak, Agnieszka, et al.
Publicado: (2021) -
Incretin hormones and type 2 diabetes
por: Nauck, Michael A., et al.
Publicado: (2023) -
The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010)